Exciting Media Attention About Fragile X Clinical Trials

By |2012-09-21T10:40:33-04:00Sep 21, 2012|Keeping You Informed, News Reports and Commentaries|

The NFXF is pleased to see the media attention surrounding the latest news resulting from clinical trials for Fragile X syndrome treatments. Two members of the NFXF’s Scientific and Clinical Advisory Committee, Dr. Randi Hagerman, the NFXF’s co-founder, and Dr. Elizabeth Berry-Kravis, also a member of the NFXF’s Board of Directors, have been receiving prominent mention. The NFXF has been pleased to be able to assist its corporate partner, Seaside Therapeutics, with recruitment for this trial and others.

Load More Posts